NEW YORK – Less than two weeks ago, members of the Jackson Laboratory's Maine Cancer Genomics Initiative (MCGI) were seeing strong enrollment by cancer patients seeking somatic tumor profiling to inform their treatment or potential clinical trial options.
But MCGI Medical Director and Jax medical oncologist Jens Rueter expects that could soon change, as cancer centers and clinical trial sites across the US and beyond respond to the COVID-19 pandemic.